ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,906.94
-1.07%
Dow Jones
42,573.73
-0.97%
US Dollar vs MXN
20.6871
0.19%
Brent Oil
74.64
0.73%
Bitcoin
92,562.88
-0.11%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. TELA Bio Inc (TELA) Cotización

TELA Bio Inc

TELA Bio Inc (TELA)

NASDAQ
2.90
-0.01
(-0.34%)
Cerrado 31 Diciembre 3:00PM
Delayed by 15 minutes
2.895
-0.005
(-0.17%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
2.90
Postura de Compra
2.85
Postura de Venta
2.98
Volume Operado de la Acción
83,700
2.84 Rango del Día 2.97
2.30 Rango de 52 semanas 7.84
Capitalización de Mercado [m]
114.226M
Precio Anterior
2.91
Precio de Apertura
2.93
Hora
8804
@
2.9
Última hora de negociación
Volumen financiero
US$ 243,387
Precio Promedio Ponderado
2.9079
Volumen promedio (3 m)
245,851
Acciones en circulación
39,388,443
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.44
Beneficio por acción (BPA)
-1.18
turnover
58.45M
Beneficio neto
-46.66M

Acerca de TELA Bio Inc

TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of... TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Mostrar más

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sitio web
www.telabio.com
Sede
Wilmington, Delaware, USA
Fundado
-
TELA Bio Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker TELA. The last closing price for TELA Bio was US$2.91. Over the last year, TELA Bio shares have traded in a share price range of US$ 2.30 to US$ 7.84.

TELA Bio currently has 39,388,443 shares in issue. The market capitalisation of TELA Bio is US$114.62 million. TELA Bio has a price to earnings ratio (PE ratio) of -2.44.

TELA Últimas noticias

Más noticias

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue...

13 Diciembre 2024
GlobeNewswire Inc.

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions...

19 Noviembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

07 Noviembre 2024
Edgar (US Regulatory)

TELA Bio Reports Third Quarter 2024 Financial Results

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) --  TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions...

07 Noviembre 2024
GlobeNewswire Inc.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue...

01 Noviembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

28 Octubre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Octubre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Octubre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Octubre 2024
Edgar (US Regulatory)

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced...

24 Octubre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.01-0.3436426116842.9132.77579162.91793517CS
4-0.29-9.090909090913.193.22.692059082.86403528CS
120.165.839416058392.743.262.32458512.83334341CS
26-1.84-38.81856540084.745.1752.32271203.20983514CS
52-3.66-55.79268292686.567.842.31936704.16952404CS
156-9.32-76.268412438612.2213.72.31167256.05361008CS
260-9.65-76.892430278912.5523.5452.3864137.57862907CS

TELA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de TELA Bio?
El precio actual de las acciones de TELA Bio es US$ 2.90
¿Cuántas acciones de TELA Bio están en circulación?
TELA Bio tiene 39,388,443 acciones en circulación
¿Cuál es la capitalización de mercado de TELA Bio?
La capitalización de mercado de TELA Bio es USD 114.62M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de TELA Bio?
TELA Bio ha negociado en un rango de US$ 2.30 a US$ 7.84 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de TELA Bio?
El ratio precio/beneficio de TELA Bio es -2.44
¿Cuál es el ratio de efectivo a ventas de TELA Bio?
El ratio de efectivo a ventas de TELA Bio es 1.95
¿Cuál es la moneda de reporte de TELA Bio?
TELA Bio presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de TELA Bio?
El último ingresos anual de TELA Bio es USD 58.45M
¿Cuál es el último beneficio anual de TELA Bio?
El último beneficio anual de TELA Bio es USD -46.66M
¿Cuál es la dirección registrada de TELA Bio?
La dirección registrada de TELA Bio es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de TELA Bio?
La dirección del sitio web de TELA Bio es www.telabio.com
¿En qué sector industrial opera TELA Bio?
TELA Bio opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WATTEnergous Corporation
US$ 2.70
(556.61%)
226.21M
NXUNXU Inc
US$ 1.52
(524.49%)
572.73M
HOLOMicroCloud Hologram Inc
US$ 6.40
(166.67%)
221.85M
INTZIntrusion Inc
US$ 5.67
(162.50%)
132.97M
SMXSMX Security Matters Public Company
US$ 0.803558
(127.25%)
370.63M
ICGIntchains Group Ltd
US$ 3.39
(-63.67%)
1.77M
ABPAbpro Holdings Inc
US$ 2.10
(-53.23%)
2.17M
LITMSnow Lake Resources Ltd
US$ 0.9212
(-42.43%)
69.28M
TRAWTraws Pharma Inc
US$ 8.33
(-37.93%)
1.2M
BDMDBaird Medical Investment Holdings Ltd
US$ 1.07
(-37.79%)
153.54k
NXUNXU Inc
US$ 1.52
(524.49%)
572.73M
SMXSMX Security Matters Public Company
US$ 0.803558
(127.25%)
370.63M
VINCVincerx Inc
US$ 0.3243
(67.16%)
335.59M
XTIAXTI Aerospace Inc
US$ 0.0395
(0.00%)
292.67M
WATTEnergous Corporation
US$ 2.70
(556.61%)
226.21M

Discusión

Ver feed completo
BakedLangostino BakedLangostino 2 minutos hace
If he's going to partner, he's going to partner when he knows the full potential of the company. He'll want insurance reimbursement for all the various CNS diseases for A273 and A371. The pain and cancer pipeline may be thrown in gratis as a sweetener for a deal to close. I think he'll also want to
AVXL
knrorrel knrorrel 3 minutos hace
QMMM very well closed a/h ....good sign
QMMM
THEBEASTMUGABI THEBEASTMUGABI 4 minutos hace
So what's happening with wimi in the morning fellas ?!
WIMI
knrorrel knrorrel 4 minutos hace
QMMM SHOULD RUNNING LIKE WIMI TO $3 OR MANY MORE

MAYBE LIKE QBTS

WE WE'LL SEE

imho
QBTS QMMM WIMI
knrorrel knrorrel 5 minutos hace
nice AI/ Quantum stock
QMMM
knrorrel knrorrel 6 minutos hace
very well closed a/h ....good sign
QMMM
Steady_T Steady_T 8 minutos hace
Merck didn't "give" $500M to a Chinese company. They got something in return which you fail to mention. What it 51% of the company? Was it rights to sell the treatment in the US. What was the quid pro quo?

All you can say is that is that Merck and NWBO have not arrived at a mutually a
NWBO
mrfence mrfence 8 minutos hace
When Bill Ackman speaks,
https://i.imgflip.com/9f9nm4.jpg
U better RUN!
$FMCC~ $FNMA~
Bill Ackman expects U.S. President-elect Donald Trump to remove Fannie Mae (FNMA) and Freddie Mac (FREGP) from conservatorship,
https://finance.yahoo.com/news/bill-ackman-exp
FMCC FNMA
wadegarret wadegarret 9 minutos hace
SS- AES

Stock does look cheap. Debt to equity a bit high though at about 4 to 1. I looked up SRE, and its debt to equity about 1.5 to 1. Both companies are listed as a diversified utility, but SRE has a 16 PE going forward, while AES only around a 6 PE going forward. Also the year
AES
BakedLangostino BakedLangostino 10 minutos hace
If it's a stock-for-stock buyout, Dr. Missling is going to have to be 100% convinced that their paper is better than our paper. Otherwise, it doesn't make much sense when looking at the potential upside. Better to just take on some debt or issue some more stock to fund an aggressive solo strategy:
AVXL
jhdf51 jhdf51 10 minutos hace
Same gibberish…zero result.

JHD
COOP
Steady_T Steady_T 16 minutos hace
And you base that prediction on what? Flaskworks won’t be approved commercially until second half of 2026 at the earliest. Take that to the bank!
NWBO
gp22 gp22 17 minutos hace
$BKYI: Bio-Key AI Inc.: Total shares 3.7M.
AI Drone & Autonomus Vehicle play. Exact match to $WKEY w/ much lower share count. Can make a $NUKK type move. Started getting hot on Monday. Likely a powerful move is underway. Heads up.
BKYI NUKK WKEY
gp22 gp22 17 minutos hace
$BKYI: Bio-Key AI Inc.: Total shares 3.7M.
AI Drone & Autonomus Vehicle play. Exact match to $WKEY w/ much lower share count. Can make a $NUKK type move. Started getting hot on Monday. Likely a powerful move is underway. Heads up.
BKYI NUKK WKEY
quester614 quester614 17 minutos hace
That's right Auctus didn't have to sell one share of XERI to have the loan settled. IMO Even though XERI may not owe Auctus anymore they have stayed in negotiations with Auctus. MORE DUFFY BS THAT SOUNDS GOOD. LOLOLOL
XERI
Richie R Richie R 19 minutos hace
Wow....
nowwhat2 nowwhat2 20 minutos hace
Seems like quite a rabbit hole topic that
Just spent about an hour going down it
Giving up
GME
Steady_T Steady_T 23 minutos hace
So after reading you response, there was "no finding of futility".

Thanks
NWBO
JustGoDeep JustGoDeep 24 minutos hace
Classic Bought High, Sold Low, Sour Grapes Crap.
BIEL
Steady_T Steady_T 25 minutos hace
It has a duty to provide share holder value in the long term or the short term. Management and shareholders have to decide which they prefer.
NWBO
Steady_T Steady_T 26 minutos hace
What the heck do you care about how other investors view management?

You vote with you own money based on how you perceive the situation.

Do you need others to agree with you to feel good about your choices?With that logic you can also blame the pumpers for being so com
NWBO
Steady_T Steady_T 30 minutos hace
I like your theory. But then I also thought that Rett would be approved. So what do I know.

It does seem that MIssling may not be as good a trial planner as he would like to believe. It also seems that he is an excellent manager of finance and corporate positioning.

In
AVXL
StockItOut StockItOut 31 minutos hace
You claim those Note payees are Auctus. funny.
XERI
jog49 jog49 34 minutos hace
"Any news today?

Or ackman words today?

Or nothin but end of the year?"

IT'S #3 AND #3 ONLY.
FNMA
Sleepy$$$ Sleepy$$$ 34 minutos hace
OLVI announces 1,650% Fourth Quarter Growth for Olive Tree People Inc.

OLVI

Su Consulta Reciente

NASDAQ
TELA
TELA Bio
NASDAQ
LNSR
LENSAR
NASDAQ
CDMVX
Ci Global Dividend Oppor...
AMEX
SPXU
ProShares UltraPro Short...
LSE
ZED
Zenova
BOV
SAPR4R
SANEPAR PN
BINA
SNTBTC
StatusNetwork
LSE
GW40
Morg.st.b.v 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados